{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:21:51Z","timestamp":1790266911611,"version":"4.1.0"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Currently available and recommended options for the treatment of pulmonary aspergillosis include the triazoles, echinocandins, and amphotericin B products. These therapies have significant limitations. Only the azoles are available orally, but their use is often limited by toxicities, drug\u2013drug interactions, pharmacokinetic variability, and emerging resistance. While the echinocandins are safe agents and may have a role in combination therapy, they are unproven as monotherapy. Amphotericin B preparations are toxic and require intensive monitoring. Finally, aspergillosis continues to be a disease conferring substantial morbidity and mortality, and clinical trials have not identified a therapeutic approach clearly associated with improved outcomes. As a result, there is a great need for new options in the treatment of invasive aspergillosis. Ideally, such options would be safe, have high oral bioavailability, have favorable pharmacokinetics to sequestered sites and retain activity against azole-resistant isolates. Reassuringly, there is a robust pipeline of novel therapies in development. Rezafungin (a once-weekly dosed echinocandin) and ibrexafungerp (oral agent with same mechanism of action as echinocandins) will likely be reserved for combination therapy or refractory\/intolerance scenarios with no other options. Inhaled opelconazole is an attractive option for combination therapy and prophylaxis of pulmonary aspergillosis. Development of an oral form of amphotericin B that avoids nephrotoxicity and electrolyte disturbances is an exciting development. Finally, olorofim and fosmanogepix, two agents with novel mechanisms of action and oral formulations, hold significant potential to challenge the triazole antifungals place as preferred therapies. However, many questions remain regarding these novel agents, and at the time of this writing, none of these agents have been robustly studied in Phase III studies of aspergillosis, and so their promise remains investigational.<\/jats:p>","DOI":"10.1055\/s-0043-1776776","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T18:36:22Z","timestamp":1703702182000},"page":"061-068","source":"Crossref","is-referenced-by-count":13,"title":["Antifungal Therapies for Aspergillus spp.: Present and Future"],"prefix":"10.1055","volume":"45","author":[{"given":"Gregory A.","family":"Eschenauer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"T F Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"R Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"T J Walsh","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"O A Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"P G Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"C Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"K A Marr","year":"2015","journal-title":"Ann Intern Med"},{"issue":"S 01","key":"ref8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"A J Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"J A Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"J A Maertens","year":"2021","journal-title":"Lancet"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/jof7020076","article-title":"Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients","volume":"7","author":"M E Klatt","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"08","key":"ref12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"E Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"L L Benitez","year":"2019","journal-title":"Drugs"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/jac\/dkr233","article-title":"Peripheral neuropathy in patients on long-term triazole antifungal therapy","volume":"66","author":"C G Baxter","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"e01511-20","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"C Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"A Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"M L Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"W B Park","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"106711","DOI":"10.1016\/j.ijantimicag.2023.106711","article-title":"Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial","volume":"61","author":"A Veringa","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"S 01","key":"ref20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","article-title":"Pharmacology of itraconazole","volume":"61","author":"K De Beule","year":"2001","journal-title":"Drugs"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/dkg089","article-title":"A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution","volume":"51","author":"M D Johnson","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"e01723-18","DOI":"10.1128\/AAC.01723-18","article-title":"Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects","volume":"62","author":"J Lindsay","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1093\/jac\/dkx295","article-title":"Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation","volume":"72","author":"J Lindsay","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"e02353-20","DOI":"10.1128\/AAC.02353-20","article-title":"Variability of hydroxy-itraconazole in relation to itraconazole bloodstream concentrations","volume":"65","author":"N P Wiederhold","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"T J Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"M H Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"A V Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"T Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/dky517","article-title":"Emerging threat of triazole-resistant Aspergillus fumigatus","volume":"74","author":"J M Rybak","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"P P Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/cid\/cix297","article-title":"Changes in in vitro susceptibility patterns of aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999-2015","volume":"65","author":"S T Heo","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"O A Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"A J Ullmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/TP.0000000000001050","article-title":"Antifungal prophylaxis in lung transplant recipients","volume":"100","author":"T S Patel","year":"2016","journal-title":"Transplantation"},{"issue":"10","key":"ref35","first-page":"1621","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"M S Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"D W Denning","year":"2016","journal-title":"Eur Respir J"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"F Lamoth","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/jof8080857","article-title":"Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents","volume":"8","author":"N P Wiederhold","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2021.03.005","article-title":"Antifungals in clinical use and the pipeline","volume":"35","author":"M D Johnson","year":"2021","journal-title":"Infect Dis Clin North Am"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"D R Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"e02280-16","DOI":"10.1128\/AAC.02280-16","article-title":"In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection","volume":"61","author":"T Colley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"79","author":"T I Saari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial","volume":"78","author":"P G Pappas","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1776776.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:19:17Z","timestamp":1730809157000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1776776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":43,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1776776","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}